Clinical Trial Detail

NCT ID NCT03761914
Title Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sellas Life Sciences Group
Indications

colorectal cancer

ovarian cancer

fallopian tube cancer

Advanced Solid Tumor

peritoneum cancer

acute myeloid leukemia

lung small cell carcinoma

triple-receptor negative breast cancer

Therapies

Galinpepimut-S

Galinpepimut-S + Pembrolizumab

Pembrolizumab

Sargramostim

Age Groups: adult senior

No variant requirements are available.